Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 401–500 of 1,002
Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines
Zhang, Z., Golomb, L., & Meyerson, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2428 · Cited by 59
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Steenbruggen, T. G., van Ramshorst, M. S., Kok, M., Linn, S. C., Smorenburg, C. H., & Sonke, G. S. (2017) · Drugs · doi:10.1007/s40265-017-0774-5 · Cited by 62
“Everolimus combined with tamoxifen resulted in a similar improvement in DFS in AI-resistant MBC patients (HR 0.54, 95% CI 0.36–0.81, p = 0.0021) and improvement in OS after a median follow- up of 24 months (HR 0.45, 95% CI 0.24–0.81, p = 0.007).”
BackgroundInfluentialAdditivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 70
“Both drug combinations were justified by preclinical evidence of synergy 25,27 , in the first case by a 3-to 10-fold potentiation between palbociclib and tamoxifen in three HR + breast cancer cell lines 28 and in the second case by an average of 5% more cancer cell lysis than expected by…”
InfluentialInhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy
Lyou, Y., Habowski, A. N., Chen, G. T., & Waterman, M. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13963 · Cited by 58
miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells
Lulla, A. R., Slifker, M. J., Zhou, Y., Lev, A., Einarson, M. B., Dicker, D. T., & El‐Deiry, W. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1767 · Cited by 57
“Contemporary CDK4/6 inhibitors work best in a subset of breast cancers (8), which must express proficient retinoblastoma (Rb) protein for therapeutic benefit.”
BackgroundTostivint, E. P., Kirova, Y., Lusque, A., Campone, M., Geffrelot, J., Mazouni, C., Mailliez, A., Pasquier, D., Madranges, N., Firmin, N., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6831-9 · Cited by 56
Robinson, A. M., Rathore, R., Redlich, N. J., Adkins, D. R., VanArsdale, T. L., Tine, B. A. V., & Michel, L. S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2098-8 · Cited by 57
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 60
Thein, K. Z., Htut, T. W., Ball, S., Swarup, S., Sultan, A., & Oo, T. H. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05783-3 · Cited by 58
“…(detec on bias) Incomplete outcome data (a ri on bias) Free of selec ve repor ng (repor ng bias) PALOMA 1 (Finn et al., 2015) + + − + + + PALOMA 2 (Finn et al., 2016) + + + + + + PALOMA 3 (Cristofanilli et al., 2016) + + + + + + MONARCH 2 (Sledge et al., 2017) + + + + + + MONARCH 3 (Goetz et…”
Wallwiener, M., Matthies, L., Simoes, E., Keilmann, L., Hartkopf, A. D., Sokolov, A. N., Walter, C. B., Sickenberger, N., Wallwiener, S., Feisst, M., et al. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.8210 · Cited by 55
“In spite of improvement in progression-free survival (PFS) through promising targeted therapy options for hormone receptor-positive breast cancer, metastatic breast cancer remains an incurable disease [2-7].”
BackgroundBonechi, M., Galardi, F., Biagioni, C., Luca, F. D., Bergqvist, M., Neumüller, M., Guarducci, C., Boccalini, G., Gabellini, S., Migliaccio, I., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24700 · Cited by 55
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 63
Bidard, F., Kiavué, N., Jacot, W., Bachelot, T., Dureau, S., Bourgeois, H. P., Gonçalvès, A., Brain, E. G. C., Ladoire, S., Dalenc, F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00456 · Cited by 55
Layman, R. M., Han, H. S., Rugo, H. S., Stringer-Reasor, E. M., Specht, J. M., Dees, E. C., Kabos, P., Suzuki, S., Mutka, S. C., Sullivan, B. F., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00034-2 · Cited by 59
Self-citationCyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence
Vernieri, C., Ligorio, F., Tripathy, D., & Longo, V. D. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.06.014 · Cited by 60
Waller, J., Mitra, D., Mycock, K., Taylor‐Stokes, G., Milligan, G., Zhan, L., & Iyer, S. S. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00239 · Cited by 59
“Reduction 20 (77) 9 (90) 11 (69) 12 (92) 6 (55) Increase 1 (4) 0 1 (6) 0 1 (9) Interruption 1 (4) 0 1 (6) 0 1 (9) Delay 4 (15) 1 (10) 3 (19) 1 (8) 3 (37)”
InfluentialQin, Q., Li, X., Liang, X., Zeng, L., Wang, J., Sun, L., & Zhong, D. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13521 · Cited by 58
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Jhaveri, K. L., Burris, H. A., Yap, T. A., Hamilton, E. P., Rugo, H. S., Goldman, J. W., Dann, S. G., Liu, F., Wong, G. Y., Krupka, H. I., et al. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944109 · Cited by 61
“Significant neutropenia may be managed by dose modification The PALOMA-2 trial of palbociclib plus letrozole [40], and the PALOMA-3 trial of palbociclib plus fulvestrant reported a manageable safety profile [69].”
Self-citationMo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01642-5 · Cited by 60
Cardiotoxicity in breast cancer treatment: Causes and mitigation
Valiyaveettil, D., Joseph, D. M., & Malik, M. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100760 · Cited by 65
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 56
Giedt, R. J., Pathania, D., Carlson, J., McFarland, P. J., del Castillo, A. F., Juric, D., & Weissleder, R. (2018) · Nature Communications · doi:10.1038/s41467-018-07002-6 · Cited by 58
Dai, M., Boudreault, J., Wang, N., Poulet, S., Daliah, G., Yan, G., Moamer, A., Burgos, S. A., Sabri, S., Ali, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2121 · Cited by 57
Albanell, J., Martínez, M. T., Ramos, M., O’Connor, M., de la Cruz‐Merino, L., Santaballa, A., Martínez-Jáñez, N., Moreno, F., Fernández, I., Alarcón, J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.010 · Cited by 60
Navarro-Yepes, J., Kettner, N. M., Rao, X., Bishop, C. S., Bui, T. N., Wingate, H. F., Raghavendra, A. S., Wang, Y., Wang, J., Şahin, A. A., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0705 · Cited by 59
Maharati, A., & Moghbeli, M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04434-7 · Cited by 55
“PI3K or mTOR inhibitors are used to restrain drug resistance, underscoring the critical role of PI3K/AKT/mTOR in endocrine therapy resistance [79, 80].”
BackgroundInhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Herrera-Abreu, M. T., Guan, J., Khalid, U., Ning, J., Costa, M. R., Chan, J., Li, Q., Fortin, J., Wong, W., Perampalam, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53837-7 · Cited by 55
Bone Metastasis: Current State of Play
Turpin, A., Duterque‐Coquillaud, M., & Vieillard, M.-H. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.10.012 · Cited by 61
“Line 1 23.2% palbociclib-letrozole vs. 21.6% letrozole (bone only) NS PALOMA-2 Finn, 2016 [16] Randomized phase 3 study.”
InfluentialClinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors
Gupta, S., Caza, T. N., Herrmann, S. M., Sakhiya, V., & Jhaveri, K. D. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.11.033 · Cited by 53
“Hypophosphatemia 0 (0) 7 (4) 0 (0) 7 (3)”
Marazzi, F., Orlandi, A., Manfrida, S., Masiello, V., Leone, A. D., Massaccesi, M., Moschella, F., Franceschini, G., Bria, E., Gambacorta, M. A., et al. (2020) · Cancers · doi:10.3390/cancers12092390 · Cited by 57
“In pivotal studies of CDK4/6 inhibitors, radiotherapy is allowed before systemic therapies beginning and it is preferable to avoid concomitance[68]–[70].”
BackgroundInhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Dang, F., Nie, L., Zhou, J. R., Shimizu, K., Chu, C., Wu, Z., Fassl, A., Ke, S., Wang, Y., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25700-6 · Cited by 52
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Kim, E., & Scott, L. J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0492-7 · Cited by 53
“Febrile neutropenia occurred in 1.8% of palbociclib plus letrozole recipients (n = 8; they were grade 3 or 4) and no placebo plus letrozole recipients in PALOMA-2 [16], and 0.9% of palbociclib plus fulvestrant recipients (n = 3; all grade 3) and 0.6% of placebo plus fulvestrant recipients (n = 1; grade 4) in PALOMA-3…”
InfluentialExtranuclear signaling by sex steroid receptors and clinical implications in breast cancer
Boonyaratanakornkit, V., Hamilton, N. M., Márquez‐Garbán, D. C., Pateetin, P., McGowan, E. M., & Pietras, R. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.010 · Cited by 56
Recent Advances in CDK Inhibitors for Cancer Therapy
Heptinstall, A. B., Adiyasa, I., Cano, C., & Hardcastle, I. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0246 · Cited by 56
Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
Johnston, S. J., & Cheung, K. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0062-x · Cited by 58
Living with Metastatic Cancer: A Roadmap for Future Research
Tometich, D. B., Hyland, K. A., Soliman, H. H., Jim, H., & Oswald, L. B. (2020) · Cancers · doi:10.3390/cancers12123684 · Cited by 54
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
Freelander, A., Brown, L. J., Parker, A. J., Segara, D., Portman, N., Lau, B., & Lim, E. (2021) · Genes · doi:10.3390/genes12020285 · Cited by 62
“Reference [31] [32] [19] [17] [16] [33] [34] [35]”
Pavlovic, D., Nićiforović, D., Papic, D., Milojevic, K., & Marković, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231205848 · Cited by 58
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Metzger, O., Mandrekar, S. J., Goel, S., Gligorov, J., Lim, E., Ciruelos, E., Loibl, S., Dockter, T., González, X., Francis, P. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511218 · Cited by 62
Self-citationNagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 53
Ismail, R. K., van Breeschoten, J., Wouters, M. W. J. M., van Dartel, M., van der Flier, S., Reyners, A. K. L., de Graeff, P., Pasmooij, A. M. G., de Boer, A., Broekman, K. E., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.11.013 · Cited by 50
The paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan, E. A., Wallis, R., Mossa, F., & Bishop, C. L. (2024) · npj Aging · doi:10.1038/s41514-024-00168-y · Cited by 62
Sun, W., O'Dwyer, P. J., Finn, R. S., Ruiz-García, A., Shapiro, G. I., Schwartz, G. K., DeMichele, A. M., & Wang, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.902 · Cited by 50
Self-citationTreatment for the endocrine resistant breast cancer: Current options and future perspectives
Liu, C., Wu, C., Petrossian, K., Huang, T., Tseng, L., & Chen, S. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.001 · Cited by 55
Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition
Chaikovsky, A. C., & Sage, J. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0201 · Cited by 53
Vernieri, C., Corti, F., Nichetti, F., Ligorio, F., Manglaviti, S., Zattarin, E., Rea, C. G., Capri, G., Bianchi, G., & de Braud, F. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01271-0 · Cited by 55
Triple-negative breast cancer: new treatment strategies in the era of precision medicine
Wu, S., Wang, H., Shao, Z., & Jiang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1714-8 · Cited by 62
Migliaccio, I., Bonechi, M., McCartney, A., Guarducci, C., Benelli, M., Biganzoli, L., Leo, A. D., & Malorni, L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102136 · Cited by 59
Mouron, S. A., Manso, L., Caleiras, E. J., Rodríguez‐Peralto, J. L., Rueda, O. M., Caldas, C., Colomer, R., Quintela-Fandiño, M., & Bueno, M. J. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01398-8 · Cited by 51
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
Susanti, N. M. P., & Tjahjono, D. H. (2021) · Molecules · doi:10.3390/molecules26154462 · Cited by 54
“Palbociclib (6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]p yrido[2,3-d]pyrimidin-7-one) is the first FDA-approved CDK4/CDK6 inhibitor combined with letrozole for HR-positive/HER2-negative MBC treatment and for treatment of disease progression after endocrine therapy combined with fulvestrant…”
BackgroundBruno, L. I., Ostinelli, A., Waisberg, F., Enrico, D. H., Ponce, C., Rivero, S. G., Blanco, A., Zarbá, M., Loza, M., Fabiano, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00140 · Cited by 54
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Wander, S. A., O’Brien, N. A., Litchfield, L. M., O’Dea, D., Guimaraes, C. M., Slamon, D. J., & Goel, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac138 · Cited by 54
Self-citationTargeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia
Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 60
“Palbociclib has significant clinical activity in non-hematological cancers, demonstrating improved progression-free survival in combination with letrozole [46] or fulvestrant [47] in breast cancer.”
BackgroundGoyal, R., Chen, H., Abughosh, S., Holmes, H. M., Candrilli, S. D., & Johnson, M. L. (2023) · Cancer · doi:10.1002/cncr.34675 · Cited by 52
Grinshpun, A., Tolaney, S. M., Burstein, H. J., Jeselsohn, R. M., & Mayer, E. L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00520-7 · Cited by 56
Wilson, F. R., Varu, A., Mitra, D., Cameron, C. G., & Iyer, S. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4404-4 · Cited by 49
“The efficacy and safety of palbociclib combination therapies have been demonstrated in phase 3 clinical studies [5, 6]; however, a comparison of progression-free survival (PFS) has not been made between palbociclib and chemotherapy agents.”
BackgroundMethodInfluentialOngoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Başaran, G., Twelves, C. J., Dieras, V. C., Cortés, J., & Awada, A. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.002 · Cited by 51
Janni, W., Alba, E., Bachelot, T., Diab, S., Gil‐Gil, M., Beck, T., Ryvo, L., López‐López, R., Tsai, M. L., Esteva, F. J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4658-x · Cited by 49
“7% [25] while in MONARCH-3, the ORR with abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) was 59.”
BackgroundPDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Klein, M. E., Dickson, M. A., Antonescu, C., Qin, L.-X., Dooley, S. J., Barlas, A., Manova, K., Schwartz, G. K., Crago, A. M., Singer, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0332-y · Cited by 50
“Palbociclib can be used to successfully treat non-MDM2 amplified tumors, the most notable being HR + Her2− breast cancers [34].”
BackgroundHormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines
Matutino, A. R. B., Joy, A. A., Brezden‐Masley, C., Chia, S., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.4000 · Cited by 56
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, A. R. B., Amaro, C. P., & Verma, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818346 · Cited by 52
Gopalan, P. K., Villegas, A. G., Cao, C., Pinder-Schenck, M. C., Chiappori, A., Hou, W., Zajac‐Kaye, M., Ivey, A. M., & Kaye, F. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26424 · Cited by 53
Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
Liu, B., Liu, Z., Chen, S., Ki, M., Erickson, C., Reis-Filho, J. S., Durham, B. H., Chang, Q., de Stanchina, E., Sun, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138315 · Cited by 51
“Identifying and targeting oncogenic pathways stimulated by gain-of-function genomic alterations has resulted in major clinical advances in outcomes for patients with breast cancer (45–49).”
Mater, D. V., Gururangan, S., Becher, O. J., Campagne, O., Leary, S. E. S., Phillips, J. J., Huang, J., Lin, T., Poussaint, T. Y., Goldman, S., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28879 · Cited by 51
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
Sobhani, N., Fassl, A., Mondani, G., Generali, D., & Otto, T. (2021) · Cells · doi:10.3390/cells10020293 · Cited by 58
“However, clinical data from the PALOMA-2 trial does not support this hypothesis, because only a small number of patients resistant to CDK4/6 inhibitors were RB-negative (n = 51) [72].”
ResultA Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization
Ebenezer, O., Shapi, M., & Tuszyński, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074001 · Cited by 50
“It has been introduced in several clinical drugs [12,13], including cancer drugs [14–16] (letrozole and anastrozole), thus drawing attention to the importance of this nucleus.”
BackgroundTargeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
Ferrando‐Díez, A., Felip, E., Pous, A., Bergamino, M. A., & Vila, M. M. (2022) · Cancers · doi:10.3390/cancers14143305 · Cited by 51
Harbeck, N., Fasching, P. A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R. E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.003 · Cited by 56
Self-citationJhaveri, K. L., & Marmé, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102670 · Cited by 56
Kappel, C., Elliott, M. J., Kumar, V., Nadler, M. B., Desnoyers, A., & Amir, E. (2024) · Scientific Reports · doi:10.1038/s41598-024-53151-8 · Cited by 48
“In phase III trials, CDK4/6 inhibitors trials, palbociclib, ribociclib, and abemaciclib have shown a consistent improvement in progression-free survival (PFS) when combined with an aromatase inhibitor (AI), fulvestrant, or tamoxifen 4,5 with the hazard ratios for PFS ranging between 0.50 and 0.59.”
BackgroundInfluentialMYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
Ma, J., Li, L., Ma, B., Liu, T., Wang, Z., Ye, Q., Peng, Y., Wang, B., Chen, Y., Xu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45796-w · Cited by 56
“Pharmacological inhibitors targeting CDK4/6 have shown profound effects against several solid tumors and have been approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer 2 – 4 .”
Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Zotano, Á. G., & Arteaga, C. L. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0228 · Cited by 49
“7%) PALOMA-2 (n = 666) (41) (n = 45) Anastrozole + palbociclib: 86% Letrozole + palbociclib > letrozole Anastrozole: 26% NEO-MONARCH (38) 2 Complete cell-cycle arrest (Ki67 <2.”
Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management
Lin, N., Gaspar, L. E., & Soffietti, R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175338 · Cited by 50
Cortés, J., Im, S., Holgado, E., Pérez-García, J. M., Schmid, P., & Chávez‐MacGregor, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.011 · Cited by 52
Self-citationImmunotherapy in pancreatic adenocarcinoma—overcoming barriers to response
Rosenberg, A. J., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.13 · Cited by 49
“In breast cancer, inhibitors of CDK4/6 demonstrated efficacy in combination with endocrine therapy for hormone-responsive breast cancer in the metastatic setting (126,127).”
BackgroundCCRK is a novel signalling hub exploitable in cancer immunotherapy
Mok, M. T. S., Zhou, J., Tang, W., Zeng, X., Oliver, A. W., Ward, S. E., & Cheng, A. S. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.008 · Cited by 53
“The enthusiasm for CDK inhibitors was thus dampened, until a relatively selective CDK4/6 inhibitor Palbociclib was recently approved by the FDA for treating HR and HER2 metastatic breast cancer (Finn et al., 2016).”
InfluentialCombination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clark, A. S., McAndrew, N. P., Troxel, A. B., Feldman, M. D., Lal, P., Rosen, M. A., Burrell, J. A., Redlinger, C., Gallagher, M., Bradbury, A. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0790 · Cited by 49
“Clin Cancer Res; 25(7) April 1, 2019 Clinical Cancer Research 2074”
BackgroundResultInfluentialRaschi, E., & De Ponti, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
Clatot, F., Perdrix, A., Beaussire, L., Lequesne, J., Lévy, C., Emile, G., Bubenheim, M., Lacaille, S., Calbrix, C., Augusto, L., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01290-x · Cited by 48
Retinoblastoma protein expression and its predictors in triple-negative breast cancer
Patel, J. M., Goss, A. J., Garber, J. E., Torous, V. F., Richardson, E. T., Haviland, M. J., Hacker, M. R., Freeman, G. J., Nalven, T., Alexander, B. M., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0160-4 · Cited by 52
Managing therapeutic resistance in breast cancer: from the lncRNAs perspective
Peng, L., Jiang, J., Tang, B., Nice, E. C., Zhang, Y., & Xie, N. (2020) · Theranostics · doi:10.7150/thno.49922 · Cited by 54
“CDK4/6 inhibitors such as palbociclib [97], ribociclib [98] and abemaciclib [99] combined with endocrine agents have exhibited significant PFS benefit and are approved by the FDA as the standard treatment for ER+, HER2- advanced BC patients (Figure 1).”
BackgroundCDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
Ben-Aharon, O., Magnezi, R., Leshno, M., & Goldstein, D. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0175 · Cited by 49
“4 months, respectively, in the biomarkerdriven targeted therapies [19, 21, 22, 24, 25, 33, 38, 43, 46, 48, 49]; For non-biomarker-driven targeted therapies, the improvement was 4.”
BackgroundNew therapeutic opportunities for women with low-grade serous ovarian cancer
Moujaber, T., Balleine, R. L., Gao, B., Madsen, I., Harnett, P. R., & DeFazio, A. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0191 · Cited by 56
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 70
Durairaj, C., Ruiz-García, A., Gauthier, E. R., Huang, X., Lu, D. R., Hoffman, J., Finn, R. S., Joy, A. A., Ettl, J., Rugo, H. S., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000589 · Cited by 48
Self-citationPreusser, M., Mattos‐Arruda, L. D., Thill, M., Criscitiello, C., Bartsch, R., Ruhstaller, T., de Azambuja, E., & Zielinski, C. C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000368 · Cited by 49
“8% rate of febrile neutropenia in the experimental arm and none in the control arm.(41) The phase III PALOMA-3 trial randomised 521 women with pretreated HR-positive/HER2-negative MBC— regardless of menopausal status—to receive either fulvestrant plus palbociclib or fulvestrant plus placebo.”
BackgroundMethodInfluentialFasching, P. A., Gaß, P., Häberle, L., Volz, B., Hein, A., Hack, C. C., Lux, M. P., Jud, S. M., Hartmann, A., Beckmann, M. W., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05198-9 · Cited by 52
Self-citationMulti-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer
Turanlı, B., Karagoz, K., Bidkhori, G., Sinha, R., Gatza, M. L., Uhlén, M., Mardinoğlu, A., & Arğa, K. Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00420 · Cited by 49
Fountzilas, E., Koliou, G.-A., Vozikis, A., Rapti, V., Nikolakopoulos, A., Boutis, A. L., Christopoulou, A. N., Kontogiorgos, I., Karageorgopoulou, S., Lalla, E., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000774 · Cited by 48
Zhang, P., Xu, B., Gui, L., Wang, W., Xiu, M., Zhang, X., Sun, G., Zhu, X., & Zou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00271-2 · Cited by 48
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 53
Hou, J., He, Z., Liu, T., Chen, D., Wang, B., Wen, Q., & Zheng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.755053 · Cited by 58
“3 The Mechanisms of Resistance to Proliferative Signaling Targeted Therapies Cell cycle progression related genes like CDKs have been considered as therapeutic targets by regulating proliferative signaling in various cancers, however, various clinical trials reported that monotherapy with CDK4/6 inhibitors has failed…”
BackgroundThe RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer
Zhou, W., Wang, W., Liang, Y., Jiang, R., Qiu, F.-S., Shao, X., Liu, Y., Fang, L., Ni, M., Yu, C.-H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39854-y · Cited by 49
“receptor (ER)-positive, Erb-B2 Receptor Tyrosine Kinase 2 (HER2)- negative advanced breast cancer in combination with endocrine therapy 6,7 .”
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Augereau, P., Patsouris, A., Bourbouloux, E., Gourmelon, C., Lacourtoisie, S. A., Rigaud, D. B., Soulié, P., Frenel, J., & Campone, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693195 · Cited by 50
Precision Medicine in Hormone Receptor-Positive Breast Cancer
Nasrazadani, A., Thomas, R. A., Oesterreich, S., & Lee, A. V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00144 · Cited by 51
“In phase III PALOMA-2 and PALOMA-3 trials, Palbociclib in combination with an AI or SERD, respectively, demonstrated improvement with regard to PFS but not OS thus far in patients with advanced HR+ Her2− disease (58, 59).”
BackgroundSollena, P., Nikolaou, V. A., Soupos, N., Kotteas, E. A., Voudouri, D., Stratigos, A., Fattore, D., Annunziata, M. C., Orlandi, A., Nardo, L. D., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05914-w · Cited by 49
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Somaiah, N., & Tap, W. D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102668 · Cited by 53
A single institution experience with palbociclib toxicity requiring dose modifications
Gong, J., Cho, M. T., Yu, K. W., Waisman, J. R., Yuan, Y., & Mortimer, J. E. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4606-9 · Cited by 45
“Most recently, the PALOMA 2 trial confirmed the favorable results of PALOMA 1 in a larger population of patients [3].”
BackgroundResult
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.